ExThera Medical Corporation, based in Martinez, California, is a pioneering MedTech company specializing in the development of advanced blood filtration systems. The company's flagship product, the Seraph 100 Affinity Blood Filter, is designed to capture and reduce pathogens in the bloodstream during infections. This innovative device works by adsorbing harmful substances onto its proprietary surface, thereby reducing their concentration in the blood without adding any foreign substances. The treated blood is then returned to the patient with blood cells intact, ensuring minimal disruption to the body's natural processes.

ExThera Medical primarily serves high-risk patient populations suffering from drug-resistant and drug-susceptible bloodstream infections. The company operates within the medical technology market, focusing on therapeutic applications that address critical health challenges. The Seraph 100 device has received FDA Emergency Use Authorization (EUA) for use as an adjunctive treatment for COVID-19, highlighting its potential in combating severe infections.

The business model of ExThera Medical revolves around the development, manufacturing, and distribution of its proprietary blood filtration devices. Revenue is generated through the sale of these devices to healthcare providers and institutions. The company's products are particularly valuable in hospital settings where patients are at high risk of severe infections.

Keywords: blood filtration, pathogens, bloodstream infections, MedTech, Seraph 100, FDA EUA, COVID-19 treatment, high-risk patients, therapeutic applications, medical technology.